Centiva Capital, LP Supernus Pharmaceuticals, Inc. Transaction History

Centiva Capital, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$25.99 - $33.85 $304,576 - $396,688	11,719 New	11,719 $313,000
Q4 2023 Feb 14, 2024	BUY	$22.72 - $29.68 $193,983 - $253,407	8,538 New	8,538 $247,000
Q1 2023 May 15, 2023	BUY	$34.93 - $42.03 $243,706 - $293,243	6,977 New	6,977 $252,000
Q2 2020 Aug 14, 2020	SELL	$17.09 - $24.89 $196,278 - $285,861	-11,485 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$14.45 - $24.69 $165,958 - $283,564	11,485 New	11,485 $207,000

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.93B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Centiva Capital, LP with notifications on news.